Chong Kun Dang Pharmaceutical (185750) Fundamentals 2026 — P/E 11.1x, Revenue Analysis | SniperIQ
Chong Kun Dang Pharmaceutical (185750) is a KR-listed Healthcare company in Medical - Pharmaceuticals with a market capitalization of ₩870.9B, trading at ₩66100.00 on the KSC. This SniperIQ fundamentals page covers Chong Kun Dang Pharmaceutical's valuation (P/E 11.1x, P/B 0.9x), profitability (net margin 4.5%), revenue (₩1.69T in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Chong Kun Dang Pharmaceutical's market cap?
Chong Kun Dang Pharmaceutical (185750) has a market capitalization of approximately ₩870.9B, trading at ₩66100.00 on the KSC. Market cap moves with the live share price.
What is Chong Kun Dang Pharmaceutical's P/E ratio?
Chong Kun Dang Pharmaceutical's trailing twelve-month P/E ratio is 11.1x, with a price-to-book (P/B) of 0.9x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Chong Kun Dang Pharmaceutical?
Chong Kun Dang Pharmaceutical runs a net profit margin of 4.5%, a gross margin of 29.7%, and an operating margin of 4.7%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Chong Kun Dang Pharmaceutical generate?
Chong Kun Dang Pharmaceutical reported revenue of ₩1.69T for fiscal year 2025, with net income of ₩77.8B and earnings per share (EPS) of 5882.09. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Chong Kun Dang Pharmaceutical pay a dividend?
Chong Kun Dang Pharmaceutical offers a trailing dividend yield of about 0.8%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.
Is Chong Kun Dang Pharmaceutical financially healthy?
Chong Kun Dang Pharmaceutical carries a debt-to-equity ratio of 0.36x and a current ratio of 2.00x, with a market beta of -0.43. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Chong Kun Dang Pharmaceutical a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Chong Kun Dang Pharmaceutical (185750) the key facts are: market cap ₩870.9B, P/E 11.1x, revenue ₩1.69T, 52-week range 63000-106800. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Chong Kun Dang Pharmaceutical's full fundamentals live
Get Chong Kun Dang Pharmaceutical's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.